Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2012 Results
Date:11/7/2012

tion of Vanda's and its partners' clinical trials; a failure of Vanda's products, product candidates or partnered products to be demonstrably safe and effective; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its revenues, costs, expenses and liabilities; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
2. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Vanda Pharmaceuticals Reports First Quarter 2012 Results
9. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 26, 2011 NuMe Health LLC, a biotechnology company ... today announced that it has closed a series A-1 ... chief executive officer.  The $675,000 financing was led by ... a larger series A round. The funds from the ...
... 2011 Reportlinker.com announces that a new ... catalogue: China Cardiac Catheters ... http://www.reportlinker.com/p0575380/China-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital market data ...
Cached Medicine Technology:NuMe Health Announces Closing of Series A-1 Financing Round 2NuMe Health Announces Closing of Series A-1 Financing Round 3NuMe Health Announces Closing of Series A-1 Financing Round 4NuMe Health Announces Closing of Series A-1 Financing Round 5China Cardiac Catheters and Guidewires - Market Trends Till 2016 2China Cardiac Catheters and Guidewires - Market Trends Till 2016 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... 5, 2008--Worldwide, an average 95.4 percent of LASIK patients ... first review of the world body of scientific literature, ... announced today. , With 16.3 million patients having ... clinical study and technological innovation behind it, LASIK is ...
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... Following Bi-Partisan Senate Letter, asks Lawmakers,to Reject Proposed ... Make,Reform Much More Difficult to Achieve, Letter ... WASHINGTON, March 7 The Council for Quality,Respiratory ... leading home oxygen,therapy providers and manufacturers who provide ...
... chief of developmental neurobiology at the Medical College of ... has received the 2008 Mathilde Solowey Lecture Award in ... for Advanced Education in the Sciences, honors young or ... edge, translational and of broad importance. , Dr. Mei ...
... generated by ... physicians in SEMI program, DETROIT, March 7 ... 2.5 million electronic prescriptions written in,the state of Michigan in 2007 ... Initiative (SEMI) -- helping drive,Michigan to fifth in the nation in ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... be exhibiting its AspirinWorks(R) Test at the,American College ... 2008 conference is being held March 12-14 at ... will be on-hand at booth #807 during ACOFP ...
Cached Medicine News:Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 2Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 4Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 5Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 6Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 3
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
... can be held at angles up to 45° ... in spill column, finger grooves for a non-slip ... 7 feet of regular oxygen tubing. The ... size and sustain optimum mist concentration at every ...
Medicine Products: